Trial Profile
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Eribulin (Primary)
- Indications Bladder cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Feb 2024 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 02 Feb 2024 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.
- 02 Jun 2023 Status changed from recruiting to active, no longer recruiting.